Our Team

Arpeggio comprises a wide and diverse skill set. From traditionally-trained molecular biologists to experts in machine learning, we bring a unique perspective to the field of gene regulatory inference. We are located in Boulder, Colorado.

 
 
  Joey Azofeifa, PhD   Founder, President, and Chief Science Officer  Joey developed the core intellectual property that precipitated the founding of Arpeggio Biosciences as part of his doctoral thesis in the lab of Professor Robin Dowell at the University of Colorado. He has worked in both high throughput sequencing analysis and assay development, applying his training in statistics and machine learning to develop novel approaches to allaying the impact of biological perturbations such as drug effects. Joey received his PhD in Computer Science from the University of Colorado.

Joey Azofeifa, PhD

Founder, President, and Chief Science Officer

Joey developed the core intellectual property that precipitated the founding of Arpeggio Biosciences as part of his doctoral thesis in the lab of Professor Robin Dowell at the University of Colorado. He has worked in both high throughput sequencing analysis and assay development, applying his training in statistics and machine learning to develop novel approaches to allaying the impact of biological perturbations such as drug effects. Joey received his PhD in Computer Science from the University of Colorado.

  Daniel Weaver, PhD   Founder and Chief Executive Officer  Dan has worked for over 25 years at the junction between life science and computer science with an unwavering commitment to improve human health. He has most recently pursued these passions as Founder and CEO of Boulder BioConsulting, Inc. and as Senior Product Manager for Research and Development IS at PerkinElmer Informatics. Previously, Dan was Director of Scientific Computing at Array BioPharma where he led all aspects of bioinformatic and scientific software development and acquisition. Dan received his PhD in Development Biology and Genetics from the University of Colorado.

Daniel Weaver, PhD

Founder and Chief Executive Officer

Dan has worked for over 25 years at the junction between life science and computer science with an unwavering commitment to improve human health. He has most recently pursued these passions as Founder and CEO of Boulder BioConsulting, Inc. and as Senior Product Manager for Research and Development IS at PerkinElmer Informatics. Previously, Dan was Director of Scientific Computing at Array BioPharma where he led all aspects of bioinformatic and scientific software development and acquisition. Dan received his PhD in Development Biology and Genetics from the University of Colorado.

 
 
  Joel Basken, PhD   Principal Scientist  Joel has researched human disease and therapeutic interventions for over a decade, working with melanoma and type 1 diabetes. He focused on drug resistance, protein biochemistry and pathway signaling networks in melanoma, and population genetics and inflammatory biomarkers in type 1 diabetes. Joel received his PhD in Molecular Biology and Biochemistry from the University of Colorado.

Joel Basken, PhD

Principal Scientist

Joel has researched human disease and therapeutic interventions for over a decade, working with melanoma and type 1 diabetes. He focused on drug resistance, protein biochemistry and pathway signaling networks in melanoma, and population genetics and inflammatory biomarkers in type 1 diabetes. Joel received his PhD in Molecular Biology and Biochemistry from the University of Colorado.

  Maria Lai, PhD   Principal Scientist  Maria has over 10 years of experience with mammalian cell culture and mouse models. She previously focused on genes regulating retinal vascular development with Dr. Harald Junge's group at the University of Colorado at Boulder and signaling pathways involved in cancer progression with Dr. Alok Bhushan's group in the College of Pharmacy at Idaho State University. Maria received her PhD in Molecular, Cellular, and Developmental Biology from the University of Colorado.

Maria Lai, PhD

Principal Scientist

Maria has over 10 years of experience with mammalian cell culture and mouse models. She previously focused on genes regulating retinal vascular development with Dr. Harald Junge's group at the University of Colorado at Boulder and signaling pathways involved in cancer progression with Dr. Alok Bhushan's group in the College of Pharmacy at Idaho State University. Maria received her PhD in Molecular, Cellular, and Developmental Biology from the University of Colorado.

 
 
  Ryan Langendorf, PhD   Data Scientist  Ryan studies causality in complex systems, developing novel ways to infer interactions from dynamic multivariate observational data. He has over a decade of experience in experimental design and computational thinking spanning the scales of life from gene regulatory pathways to social behavior to emergent ecosystem dynamics, and believes in combining data and theory to help people live empirically. Ryan received his PhD in Environmental Studies from the University of Colorado.

Ryan Langendorf, PhD

Data Scientist

Ryan studies causality in complex systems, developing novel ways to infer interactions from dynamic multivariate observational data. He has over a decade of experience in experimental design and computational thinking spanning the scales of life from gene regulatory pathways to social behavior to emergent ecosystem dynamics, and believes in combining data and theory to help people live empirically. Ryan received his PhD in Environmental Studies from the University of Colorado.

  Laura Norris   Administrator  Laura has worked in management, leadership, and communication positions for over a decade. She is skilled in building up small businesses and has previously worked as a manager for a number of companies while also independently owning and operating her own. Laura received her BS from the University of Nebraska-Lincoln in Psychology and Family Science.

Laura Norris

Administrator

Laura has worked in management, leadership, and communication positions for over a decade. She is skilled in building up small businesses and has previously worked as a manager for a number of companies while also independently owning and operating her own. Laura received her BS from the University of Nebraska-Lincoln in Psychology and Family Science.

 

Scientific Advisors

 
  Jim Winkler, PhD   Drug Discovery Advisor  Jim has worked for close to 40 years in Drug Discovery and Early Development, with a commitment and drive to bring new drugs into the clinic to help patients in need. He has experience at pharmaceutical (J&J, GSK) and biopharma (Array, FORMA, Arvinas) companies, in oncology and other therapeutic areas, and in using new technology to enhance the drug discovery paradigm. He has a PhD in Pharmacology from the Medical College of Pennsylvania.

Jim Winkler, PhD

Drug Discovery Advisor

Jim has worked for close to 40 years in Drug Discovery and Early Development, with a commitment and drive to bring new drugs into the clinic to help patients in need. He has experience at pharmaceutical (J&J, GSK) and biopharma (Array, FORMA, Arvinas) companies, in oncology and other therapeutic areas, and in using new technology to enhance the drug discovery paradigm. He has a PhD in Pharmacology from the Medical College of Pennsylvania.

  Timothy Read, PhD   Founder and Scientific Advisor  Tim is a molecular biologist focused on developing and implementing high throughput methods to interrogate how genomic sequences are read in healthy and disease settings. His graduate research focused on defining how intraspecies genetic variation results in altered transcriptional networks. Tim is currently an NIH fellow at Harvard Medical School and Brigham and Women’s Hospital and he received his PhD in Molecular, Cellular, and Developmental Biology from the University of Colorado.

Timothy Read, PhD

Founder and Scientific Advisor

Tim is a molecular biologist focused on developing and implementing high throughput methods to interrogate how genomic sequences are read in healthy and disease settings. His graduate research focused on defining how intraspecies genetic variation results in altered transcriptional networks. Tim is currently an NIH fellow at Harvard Medical School and Brigham and Women’s Hospital and he received his PhD in Molecular, Cellular, and Developmental Biology from the University of Colorado.

 
 
  Robin Dowell, PhD   Founder and Scientific Advisor  Robin has 20 years of experience in genomics research, predominantly in computational biology and bioinformatics. Her work has focused primarily on machine learning and probabilistic models for understanding transcriptional regulation. She is currently an Associate Professor in Molecular, Cellular and Developmental Biology at University of Colorado Boulder. Robin received her D.Sc. in Biomedical Engineering from Washington University in St Louis.

Robin Dowell, PhD

Founder and Scientific Advisor

Robin has 20 years of experience in genomics research, predominantly in computational biology and bioinformatics. Her work has focused primarily on machine learning and probabilistic models for understanding transcriptional regulation. She is currently an Associate Professor in Molecular, Cellular and Developmental Biology at University of Colorado Boulder. Robin received her D.Sc. in Biomedical Engineering from Washington University in St Louis.

  Bunki Bankaitis-Davis, PhD   Scientific Advisor  Bunki has over 20 years of drug and molecular diagnostic development experience in large biopharmaceutical and small biotechnology company settings. She served as co-founder and key executive of Source MDx®, a privately held molecular diagnostics company focused on the development and commercialization of whole blood, RNA transcript-based, pharmacodynamic and predictive biomarkers. Bunki received her PhD in Synthetic Organic Chemistry at the University of North Carolina, Chapel Hill.

Bunki Bankaitis-Davis, PhD

Scientific Advisor

Bunki has over 20 years of drug and molecular diagnostic development experience in large biopharmaceutical and small biotechnology company settings. She served as co-founder and key executive of Source MDx®, a privately held molecular diagnostics company focused on the development and commercialization of whole blood, RNA transcript-based, pharmacodynamic and predictive biomarkers. Bunki received her PhD in Synthetic Organic Chemistry at the University of North Carolina, Chapel Hill.

 

Business Advisors

  Joanna Money   Ms. Money brings over 20 years of experience in business and corporate development in multiple bioscience and biopharmaceutical companies. Most recently, she was Vice President of Corporate Development at Muse Bio (now Inscripta) and previously held business development roles at OPXBIO, Solix Biosystems and RxKinetics. Ms. Money received her PhD in Chemistry from Indiana University.

Joanna Money

Ms. Money brings over 20 years of experience in business and corporate development in multiple bioscience and biopharmaceutical companies. Most recently, she was Vice President of Corporate Development at Muse Bio (now Inscripta) and previously held business development roles at OPXBIO, Solix Biosystems and RxKinetics. Ms. Money received her PhD in Chemistry from Indiana University.

  Mike Carruthers   Mr. Carruthers has over 20 years of experience in serving as the Chief Financial Officer for publicly-traded pharmaceutical companies. He previously served as Interim President of Nivalis Therapeutics beginning in 2017 and Chief Financial Officer and Secretary since 2015. From 1998 to 2015, he served as Chief Financial Officer for Array BioPharma. Mr. Carruthers received a BS in accounting from the University of Colorado and a MBA from the University of Chicago.

Mike Carruthers

Mr. Carruthers has over 20 years of experience in serving as the Chief Financial Officer for publicly-traded pharmaceutical companies. He previously served as Interim President of Nivalis Therapeutics beginning in 2017 and Chief Financial Officer and Secretary since 2015. From 1998 to 2015, he served as Chief Financial Officer for Array BioPharma. Mr. Carruthers received a BS in accounting from the University of Colorado and a MBA from the University of Chicago.

  John Moore   Mr. Moore is a legal professional with more than twenty-five years of experience in the pharmaceutical and biotech arena. He previously served as general counsel of Array BioPharma and a member of Nivalis Therapeutics' Board of Directors. Mr. Moore received his JD from the University of North Carolina School of Law.

John Moore

Mr. Moore is a legal professional with more than twenty-five years of experience in the pharmaceutical and biotech arena. He previously served as general counsel of Array BioPharma and a member of Nivalis Therapeutics' Board of Directors. Mr. Moore received his JD from the University of North Carolina School of Law.